Abstract:Transforming growth factor-β (TGF-β) inhibits the proliferation of epithelial cells by altering the expression or function of various components of the cell cycle machinery. Expression of one of these components, cyclin A, is inhibited by TGF-β treatment. We have identified a 760-base pair fragment of the human cyclin A gene promoter that is sufficient to confer TGF-β responsiveness. Using this promoter fragment, we have developed a cyclin A-based luciferase reporter assay that quantitates the growth inhibitory effect of TGF-β in transient transfection assays. This assay was used to determine which domains of the type I (RI) and type II (RII) receptors were required for the antiproliferative effect of TGF-β. In parallel, the functionality of chimeric receptors, between RI and RII (RI-RII or RII-RI), was tested for TGF-β effect on gene expression using a reporter assay based on the plasminogen activator inhibitor type 1 (PAI-1) promoter. We found that TGF-β-induced inhibition of cyclin A expression was absent in RI or RII-deficient Mv1Lu cells and that this response was restored by expression of wild-type type I or type II receptors in these cells. Furthermore, expression of a single chimeric receptor, either RI-RII or RII-RI, did not confer cyclin A regulation by TGF-β. However, expression of two reciprocal chimeras (RI-RII and RII-RI) resulted in growth inhibition, similarly to wild-type receptors. In addition, chimeric receptors as well as mutant receptors with a deleted cytoplasmic domain and kinase-negative receptors inhibited TGF-β responsiveness in the cyclin A reporter assay in a dominant negative fashion. Finally, in both receptor types, the juxtamembrane domain preceding the kinase domain was essential for receptor function but the cytoplasmic tail was dispensable. Our results suggest that a functional TGF-β receptor complex is required for TGF-β-dependent down-regulation of cyclin A gene expression and illustrate the identical receptor requirements for TGF-β-induced growth inhibition and gene expression. Transforming growth factor-β (TGF-β) inhibits the proliferation of epithelial cells by altering the expression or function of various components of the cell cycle machinery. Expression of one of these components, cyclin A, is inhibited by TGF-β treatment. We have identified a 760-base pair fragment of the human cyclin A gene promoter that is sufficient to confer TGF-β responsiveness. Using this promoter fragment, we have developed a cyclin A-based luciferase reporter assay that quantitates the growth inhibitory effect of TGF-β in transient transfection assays. This assay was used to determine which domains of the type I (RI) and type II (RII) receptors were required for the antiproliferative effect of TGF-β. In parallel, the functionality of chimeric receptors, between RI and RII (RI-RII or RII-RI), was tested for TGF-β effect on gene expression using a reporter assay based on the plasminogen activator inhibitor type 1 (PAI-1) promoter. We found that TGF-β-induced inhibition of cyclin A expression was absent in RI or RII-deficient Mv1Lu cells and that this response was restored by expression of wild-type type I or type II receptors in these cells. Furthermore, expression of a single chimeric receptor, either RI-RII or RII-RI, did not confer cyclin A regulation by TGF-β. However, expression of two reciprocal chimeras (RI-RII and RII-RI) resulted in growth inhibition, similarly to wild-type receptors. In addition, chimeric receptors as well as mutant receptors with a deleted cytoplasmic domain and kinase-negative receptors inhibited TGF-β responsiveness in the cyclin A reporter assay in a dominant negative fashion. Finally, in both receptor types, the juxtamembrane domain preceding the kinase domain was essential for receptor function but the cytoplasmic tail was dispensable. Our results suggest that a functional TGF-β receptor complex is required for TGF-β-dependent down-regulation of cyclin A gene expression and illustrate the identical receptor requirements for TGF-β-induced growth inhibition and gene expression.

Transforming Growth Factor β Inhibits Platelet Derived Growth Factor-Induced Vascular Smooth Muscle Cell Proliferation via Akt-Independent, Smad-Mediated Cyclin D1 Downregulation

Krüppel-like Factor 4 Inhibits Proliferation by Platelet-derived Growth Factor Receptor Β-Mediated, Not by Retinoic Acid Receptor Α-Mediated, Phosphatidylinositol 3-Kinase and ERK Signaling in Vascular Smooth Muscle Cells*

Transforming Growth Factor-1 Downregulation of Smad 1 Gene Expression in Rat Hepatic Stellate Cells

Kruppel‐like factor 4 is involved in TGF‐beta1‐induced VSMC differentiation through trans‐activating TbetaRI expression

Platelet-deriver Growth Factor Stimulates Vascular Smooth Muscle Cell Proliferation Through AKT-FoxO Signaling Pathway

Krüppel-like Factor 4 Promotes Differentiation by Transforming Growth Factor-β Receptor-mediated Smad and P 38 MAPK Signaling in Vascular Smooth Muscle Cells

TGF-β suppresses the upregulation of MMP-2 by vascular smooth muscle cells in response to PDGF-BB

Effect of transforming growth factor-β1 on human aortic vascular smooth muscle cell phenotype switch and mechanism

Transforming growth factor-β1 inhibits interleukin-1β-induced expression of inflammatory genes and Cathepsin S activity in human vascular smooth muscle cells

Disruption of TGF-β Signaling in Smooth Muscle Cell Prevents Flow-Induced Vascular Remodeling.

Smad2 and Smad3 As Mediators of the Response of Adventitial Fibroblasts Induced by Transforming Growth Factor Β1

Mir-145-5p Inhibits Vascular Smooth Muscle Cells (vsmcs) Proliferation and Migration by Dysregulating the Transforming Growth Factor-b Signaling Cascade.

Transforming Growth Factor-β (TGF-β)-induced Down-regulation of Cyclin A Expression Requires a Functional TGF-β Receptor Complex

Ectopic Expression of Smad7 Inhibits Transforming Growth Factor-Beta Responses in Vascular Smooth Muscle Cells

Atorvastatin Calcium Inhibits PDGF-ββ-Induced Proliferation and Migration of VSMCs Through the G0/G1 Cell Cycle Arrest and Suppression of Activated PDGFRβ-PI3K-Akt Signaling Cascade

Direct Transfer Of Transforming Growth-Factor-Beta-1 Gene Into Arteries Stimulates Fibrocellular Hyperplasia

PDGF-induced Vascular Smooth Muscle Cell Proliferation is Associated with Dysregulation of Insulin Receptor Substrates.

Functional Characterization of Transforming Growth Factor Β Signaling in Smad2- and Smad3-deficient Fibroblasts*

Impact of ERK2 signaling pathway blockade on platelet-derived growth factor-induced vascular smooth muscle cells proliferation,migration and transform growth factar-β1 expression

[Role of Rac1 Activation in Platelet Derived Growth Factor-Bb Induced Proliferation and Migration in Rat Aortic Smooth Muscle Cells].

Transforming growth factor-beta receptor type 1 (TGFbetaRI) kinase activity but not p38 activation is required for TGFbetaRI-induced myofibroblast differentiation and profibrotic gene expression.